iProtics B.V. is a Leiden University and TU Munich spin‑off developing highly selective, peptide‑based immunoproteasome inhibitors for hematological malignancies such as multiple myeloma and chronic lymphocytic leukemia. By potently inhibiting all three immunoproteasome subunits while largely sparing the constitutive proteasome, iProtics aims to maintain anti‑tumor efficacy while reducing the severe cardiotoxicity and neuropathy seen with current proteasome inhibitors, with lead candidates now progressing through preclinical development under an exclusive patent license and early‑stage investor and grant support.